Poxel
Records under this name other than the patents Poxel holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,937,066 | Amino Derivatives of DIHYDRO-1,3,5-Triazine Used in the Treatment of Ischemia And/Or Reperfusion Related Diseases Formerly held In force · High confidence | In force | High confidence | |
| US 9,284,329 | Thienopyridone Derivatives Useful as Activators of Ampk Formerly held In force · High confidence | In force | High confidence | |
| US 11,850,238 | Use of a Thienopyridone Derivative in the Treatment of Adrenoleukodystrophy or Adrenomyeloneuropathy Formerly held In force · High confidence | In force | High confidence | |
| US 12,310,949 | Use of a Thienopyridone Derivative in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Formerly held In force · High confidence | In force | High confidence | |
| US 12,319,700 | Monohydrate Potassium Salt of a Thienopyridone Derivative and Its Preparation Process Formerly held In force · High confidence | In force | High confidence | |
| US 10,071,108 | Methods and Pharmaceutical Compositions for the Treatment of Hepatitis B Virus Infection Lapsed on the fee record Ended Sep 11, 2026 · Low confidence | Lapsed on the fee record | Ended Sep 11, 2026 | Low confidence |
| US 8,742,102 | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization Lapsed on the fee record Ended Jun 3, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | From the USPTO record |
| US 8,742,103 | Separation of triazine derivatives enantiomers using tartaric acid Lapsed on the fee record Ended Jun 3, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | From the USPTO record |
| US 9,365,584 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof Lapsed on the fee record Ended Jun 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 14, 2024 | From the USPTO record |
| US 9,271,984 | Treatment of type 1 diabetes Lapsed on the fee record Ended Mar 1, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | From the USPTO record |